| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Richard N Pierson | |
| Tianshu Zhang | |||
| Agnes M Azimzadeh | |||
| P2860 | cites work | Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates | Q77890140 |
| Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154 | Q77948248 | ||
| Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial | Q78667363 | ||
| Targeting LFA-1 Synergizes with CD40/CD40L Blockade for Suppression of Both CD4-Dependent and CD8-Dependent Rejection | Q79083543 | ||
| Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse | Q82097240 | ||
| A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy | Q84056960 | ||
| Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
| CD40-CD40 ligand | Q28143324 | ||
| Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies | Q28256960 | ||
| The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation | Q28586300 | ||
| Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity | Q29619700 | ||
| A novel monoclonal antibody to CD40 prolongs islet allograft survival | Q30417821 | ||
| Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice | Q33390434 | ||
| Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation | Q33814943 | ||
| Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. | Q33853487 | ||
| Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection | Q33903407 | ||
| Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab | Q34026630 | ||
| Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells | Q34054944 | ||
| Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response | Q34196228 | ||
| LFA-1-specific therapy prolongs allograft survival in rhesus macaques. | Q34364120 | ||
| CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates | Q34433847 | ||
| Humoral immune responses in CD40 ligand-deficient mice | Q34725239 | ||
| An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. | Q34870978 | ||
| Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges | Q35003473 | ||
| An antagonist mutant IL-15/Fc promotes transplant tolerance | Q35087089 | ||
| Heterologous immunity provides a potent barrier to transplantation tolerance | Q35095576 | ||
| Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner | Q56906395 | ||
| CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment | Q56907083 | ||
| CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity | Q56909606 | ||
| Transplantation tolerance induced by CTLA4-Ig | Q56909687 | ||
| CD40Lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome | Q57075423 | ||
| Stimulating PD-1???negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival1 | Q57202266 | ||
| Prolonged Blockade of CD40-CD40 Ligand Interactions by Gene Transfer of CD40Ig Results in Long-Term Heart Allograft Survival and Donor-Specific Hyporesponsiveness, But Does Not Prevent Chronic Rejection | Q61054319 | ||
| Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance | Q61651670 | ||
| CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways | Q64038816 | ||
| CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway | Q70897771 | ||
| Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40 | Q71929966 | ||
| Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells | Q72191659 | ||
| Mice deficient for the CD40 ligand | Q72610555 | ||
| A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis | Q73114791 | ||
| Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates | Q73134598 | ||
| Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody | Q73299853 | ||
| Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models | Q73311868 | ||
| Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 | ||
| Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus | Q73483737 | ||
| Anti-CD154 monoclonal antibody and thromboembolism | Q73575632 | ||
| Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand | Q73585351 | ||
| Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation | Q73618857 | ||
| Anti-CD154 monoclonal antibody and thromboembolism revisted | Q74622610 | ||
| Platelet-derived CD40L: the switch-hitting player of cardiovascular disease | Q74627856 | ||
| T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection | Q74817270 | ||
| Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates | Q77167639 | ||
| New monoclonal antibodies in renal transplantation. | Q35139796 | ||
| Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance | Q35237468 | ||
| Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade | Q35650992 | ||
| CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. | Q35675258 | ||
| Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates | Q35675449 | ||
| Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. | Q35910720 | ||
| Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection | Q35939463 | ||
| CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8 | Q36069444 | ||
| Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation | Q36229698 | ||
| Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells | Q36305532 | ||
| High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. | Q36367196 | ||
| CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade | Q36369151 | ||
| Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. | Q36417432 | ||
| A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection | Q36945001 | ||
| Platelets an inflammatory force in transplantation | Q36967343 | ||
| Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo | Q37075945 | ||
| Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection | Q37240435 | ||
| IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice | Q37292014 | ||
| T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo | Q37308435 | ||
| Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production | Q37354525 | ||
| Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection | Q37382362 | ||
| Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. | Q37382702 | ||
| Memory T cells need CD28 costimulation to remember | Q37408575 | ||
| Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Q37474929 | ||
| Costimulatory pathways in transplantation: challenges and new developments. | Q37474958 | ||
| Translating costimulation blockade to the clinic: lessons learned from three pathways | Q37474964 | ||
| Skin allograft maintenance in a new synchimeric model system of tolerance | Q37494823 | ||
| A more selective costimulatory blockade of the CD28-B7 pathway. | Q37801975 | ||
| Costimulation blockade: current perspectives and implications for therapy | Q38057977 | ||
| Targeting co-stimulatory pathways: transplantation and autoimmunity | Q38150101 | ||
| Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation | Q39265882 | ||
| Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates | Q39640425 | ||
| Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. | Q40459668 | ||
| RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. | Q40488849 | ||
| Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation | Q40578442 | ||
| The CD40 ligand expressed by human B cells costimulates B cell responses | Q41345776 | ||
| The CD40 pathway in allograft rejection, acceptance, and tolerance | Q41642375 | ||
| High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade | Q41830723 | ||
| Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall | Q41870671 | ||
| Endogenous memory CD8 T cells directly mediate cardiac allograft rejection | Q42238758 | ||
| Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner | Q42870714 | ||
| Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion | Q42941965 | ||
| Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection | Q43655794 | ||
| Anti-CD40 therapy extends renal allograft survival in rhesus macaques | Q44190483 | ||
| Programmed death-1 targeting can promote allograft survival | Q44223920 | ||
| Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation | Q44320804 | ||
| CD40-ligand in primate cardiac allograft and viral immunity | Q44435380 | ||
| Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases | Q44560131 | ||
| The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. | Q44701643 | ||
| A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation | Q44761971 | ||
| Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates | Q44765909 | ||
| Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. | Q44839204 | ||
| Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection | Q44947130 | ||
| Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. | Q45959036 | ||
| IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates | Q46427141 | ||
| Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. | Q46499903 | ||
| Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells | Q46681487 | ||
| In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy | Q47725793 | ||
| CD154 regulates primate humoral immunity to influenza | Q47869320 | ||
| Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis | Q47997496 | ||
| ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates | Q48032381 | ||
| FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. | Q51026715 | ||
| Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. | Q51541351 | ||
| Memory CD8+ T cells require CD28 costimulation. | Q51970076 | ||
| Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade. | Q51978232 | ||
| Critical, but conditional, role of OX40 in memory T cell-mediated rejection. | Q51985347 | ||
| Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. | Q52011668 | ||
| Functional responses and costimulator dependence of memory CD4+ T cells. | Q52030310 | ||
| A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. | Q52843789 | ||
| Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. | Q53013437 | ||
| Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. | Q53530309 | ||
| Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms. | Q53639153 | ||
| Critical role of OX40 in CD28 and CD154-independent rejection. | Q53905524 | ||
| Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. | Q54026447 | ||
| Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. | Q55066427 | ||
| Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody | Q56897833 | ||
| Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients | Q56900950 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 899-911 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | Update on CD40 and CD154 blockade in transplant models | |
| P478 | volume | 7 |
Search more.